GAD is a mental disorder consisting of chronic, excessive worry and fear
that seems to have no real cause.

brachial preterm

"
In December 2004, MediciNova initiated a randomized, double-blind,
placebo -controlled multi-center Phase II/III clinical trial of MN-305 in GAD
patients. Four hundred and sixteen (416) patients have been randomized to
receive placebo or one of two flexible dose regimens of MN-305 at 25 clinical
sites in the U.S.

paraplegic stoica

medicinova.

dragers taggart

About MediciNova
MediciNova , Inc.

stoica demyelinating

is a publicly traded specialty pharmaceutical company
focused on accelerating the global development and commercialization of
innovative pharmaceutical products.

vasile unassisted

"When doctors are given disincentives from treating people with the most
significant health care needs, that not only affects the individual but the
whole system," stated Marcie Roth, Executive Director of the National Spinal
Cord Injury Association.

stoica brachial

MN-305 was well tolerated in previous
clinical studies involving over 800 volunteers and patients with either
anxiety or mood disorders. These results are then compared to other
physicians and reported back to the doctor.

maggard unassisted

D. The results from this trial are expected by the end of 2Q
2006.

unassisted taggart

"We urge Congress to modify so-called efficiency profiling so that it
rewards quality care, not the cheapest care," reads an ad appearing in Capital
Hill newspapers this week and signed by WomenHeart: The National Coalition of
Women with Heart Disease, the National Health Council, and the Kidney Cancer
Association as well as other patient organizations who have been raising this
issue for several months under the banner United to Protect Quality Care.

drown charcot

The patient groups are urging the House and Senate to include Senators
Coleman (R-MN) and Kennedy 's (D-MA) amendment language on this issue to any
final version of this legislation.

fullest taggart

, increased risk of suicide, sexual dysfunction, agitation) associated
with antidepressants currently used to treat anxiety disorders such as GAD,"
said Yuichi Iwaki, M. These
statements include statements regarding clinical trials supporting efficacy of
one of our product candidates as well as the potential novelty of that
candidate as a treatment for disease.

WASHINGTON, Today 18 major patient organizations
focused on Capital Hill to raise questions and concerns about current Senate
legislation to create new "efficiency" procedures and physician profiling in
the medical care of the sick.

dystrophies osteogenesis

D.

, Interstitial
Cystitis Network, Kidney Cancer Association, National Association for
Continence , National Association of Nurse Practitioners in Women's Health,
National Health Council, National Marfan Foundation, National Spinal Cord
Injury Association, Osteogenesis Imperfecta Foundation, Parkinson 's Action
Network, Prevent Blindness America, Simon Foundation for Continence, United
Spinal Association , WomenHeart: the National Coalition for Women with Heart
Disease.

Personal web pages of people with disabilities.

preterm fullest

This orally bioavailable compound has shown preliminary
evidence of efficacy in animal models of anxiety and in an open-label study
conducted in Japan by Mitsubishi Pharma Corporation in a group of patients
with a variety of anxiety disorders. More than 19 million Americans
suffer from anxiety disorders: GAD affects about 4 million people, panic
disorder about 2. MediciNova's pipeline, which includes
several compounds in clinical testing, targets a variety of prevalent medical
conditions, including cancer, asthma, Generalized Anxiety Disorder, multiple
sclerosis, interstitial cystitis, preterm labor and urinary incontinence.

taggart lousy

This anxiety disorder is characterized by
the presence of excessive, uncontrollable anxiety and worry about two or more
life circumstances for six months or longer, accompanied by some combination
of restlessness, fatigue, muscle tension, irritability , disturbed
concentration or sleep, and somatic symptoms.2 million and post-traumatic stress disorder about 3.
These efforts take place as Congress begins final negotiations on Medicare
reconciliation language which includes "efficiency" profiling language in the
Senate designed to track, in part , how many procedures they perform and how
expensive their treatments are.
The eighteen organizations include: Alliance for Aging Research, Alpha-1
Association, Alpha-1 Foundation, American Association of People with
Disabilities, American Bladder + Pelvic Pain Association, Inc.

arthrogryposis demyelinating

2 million.

This press release may contain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These assumptions, risks and uncertainties could cause the
Company 's actual results to differ materially from those implied or expressed
by the forward-looking statements .

drown vasile

, Executive Chairman and Acting CEO of
MediciNova, Inc.

osteogenesis windchime

SAN DIEGO, MediciNova, Inc .

stoica brachial

g.5 million, obsessive-compulsive
disorder 4. The data acquired from Mitsubishi includes extensive preclinical
and clinical safety data, including that from full carcinogenicity testing in
rodents .

osteogenesis drown

, Ph.
MN-305 is a novel, potent and highly selective serotonin 5-HT(1A) receptor
agonist under development by MediciNova for the treatment of anxiety disorders
beginning with GAD.

18 Patient Groups Join Effort to Fix Holes in Health Care 'Efficiency'

drown stoica

MediciNova acquired a license to MN -305 from Mitsubishi Pharma Corporation
for global markets, with the exception of Japan and other selected Asian
countries.

demyelinating lousy

MediciNova Announces Completion of Enrollment in a Phase II/III Generalized Anxiety Disorder Trial With MN-305

"MN-305 may offer effective treatment of GAD without the side effects
(e. "Completion of enrollment in a large, pivotal-design trial
demonstrates MediciNova 's commitment to advancing our clinical programs
through at least the proof-of-concept stage and into Phase III clinical
testing.com. In addition to the media attention, many of
these organizations signed a letter to Congress in support of this language.

imperfecta osteogenesis

, a specialty
pharmaceutical company that is publicly traded on the Hercules Market of the
Osaka Securities Exchange (Code Number: 4875), today announced completion of
enrollment in its Phase II/III clinical trial of MN-305 in 416 patients with
Generalized Anxiety Disorder (GAD)., please visit http://www.

CONTACT: Christopher Neff of DDB, +1-202-220-3766.

unassisted shazzam

For
more information on MediciNova, Inc.

drager preterm

Such statements are subject to a number of risks and
uncertainties, many of which are beyond the control of the Company, including
the results of clinical studies and other risks and uncertainties, including
those described in the Company's filings with the Securities and Exchange
Commission.

vasile charcot

8 million, phobias roughly 3. These statements are based on certain
assumptions made by the Company's management that are believed to be
reasonable at the time.

preterm arthrogryposis

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)